UPC Analytics
DEEN
Übersicht · Eingereicht: 28. Okt. 2024

UPC_CFI_628/2024

EMBOLIC PROTECTION DEVICE

VerletzungHauptverletzungsklageMunich LDInfringementCase Closed
Parteien

Kläger

  • Emboline, Inc.
Vertreter: Thure Schubert (Vossius & Brinkhof UPC Litigators)

Beklagte

  • AorticLab srl
Vertreter: Sabine Agé (HOYNG ROKH MONEGIER)
Richter
  • Matthias Zigann
  • Tobias Pichlmaier
  • Petri Rinkinen
  • Elisabetta Papa
Patente
  • EP2129425
  • EP 2 129 425
CPC-Codes: A61F2230/0065, A61F2230/0006, A61F2250/0023, A61F2250/0003, A61F2/0105, A61F2002/018, A61F2250/0069, A61F2230/0067, A61F2230/0069, A61F2/011

Technologiebereich: Medical Devices · Implants

Sektor: Pharmaceutical & Medical

Ausgang
Nicht verletztNicht verletzt
Eingereicht: 28. Okt. 2024
Erste Entscheidung: 13. Jan. 2026
Sprache: English

Final decision on the merits in infringement action by Emboline, Inc. against AorticLab srl (EP 2 129 425, medical device). Court dismissed the infringement action finding the patent not infringed. The defendant's counterclaim for revocation was conditional (dependent on a finding of infringement), and since no infringement was found, no decision was made on the counterclaim. Both parties bear their own costs. Key headnotes: infringement not excluded by normal non-infringing operation if patent-compliant use remains possible; irregular use of a medical device in line with professional practice can constitute infringement; conditional counterclaim limited in scope (Rule 263.3 RoP).

Im UPC-Register öffnen
Ansprüche
Streitigall
Nicht verletztall
Hinweise: Infringement action dismissed for EP 2 129 425; conditional counterclaim for revocation not decided as condition (infringement finding) not met.